OHE Lunchtime Seminar: Early Experience with HTA of Gene Therapies in the US: Pricing and Paying for Cures
OHE Lunchtime Seminar with Steven Pearson, Founder and President of the Institute for Clinical and Economic Review (ICER). The time is rapidly approaching when health care funders and health care systems around the world must be able to manage a…
21/10/18 11:00 pm
OHE Lunchtime Seminar with Steven Pearson, Founder and President of the Institute for Clinical and Economic Review (ICER).
The time is rapidly approaching when health care funders and health care systems around the world must be able to manage a growing number of drugs offering potential cures for a wide range of illnesses. The innovation pipeline includes potential cures for haemophilia, sickle cell disease, and numerous other genetically-based conditions. Individually, each treatment will be extremely expensive, and in the aggregate their costs are projected to have a substantial impact on the affordability of health care. Stated frankly, health systems today are ill prepared to face the challenge of assessing and paying for the potential cures that will soon become available.
As the leading health technology assessment organization in the US, ICER has completed reviews of three gene therapies and is in the midst of a fourth review. Dr Steven Pearson, ICER’s President, will discuss the distinctive challenges in analysing the clinical and cost-effectiveness of these therapies, and the lessons learned to date. As part of this discussion Dr Pearson will present the early outlines of options for new methods to calculate “value-based” prices for potential cures that offer magnitudes of health gains and future cost offsets that have never been generated by traditional treatments.
Steven D. Pearson, MD, MSc is the Founder and President of the Institute for Clinical and Economic Review (ICER), an independent health technology assessment organization based in the US. Prominent among its evidence reports are ICER reviews of new drugs that include full assessments of clinical and cost-effectiveness along with suggested “value-based price benchmarks” to guide price and coverage negotiation. Dr Pearson is a Lecturer in the Department of Population Medicine at Harvard Medical School and also serves as Visiting Scientist in the Department of Bioethics at the National Institutes of Health. His published work includes over 100 articles on quality of care, the role of evidence-based medicine within the health care system, and related clinical, ethical, and organizational policy challenges. His book, No Margin, No Mission: Health Care Organizations and the Quest for Ethical Excellence, was published by Oxford University Press.
Webinar facilities will also be available for this lunchtime seminar, however registration is needed. Please send an email to firstname.lastname@example.org if you wish to join. Details of the webinar will be sent out closer to the event date.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
3rd Party Cookies
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!